Patel Priti 4
4 · Neoleukin Therapeutics, Inc. · Filed Apr 4, 2023
Insider Transaction Report
Form 4
Patel Priti
Chief Medical Officer
Transactions
- Sale
Common Stock
2023-04-03$0.69/sh−3,769$2,608→ 37,313 total - Exercise/Conversion
Common Stock
2023-03-31+10,000→ 41,082 total - Exercise/Conversion
Restricted Stock Units
2023-03-31−10,000→ 0 totalExercise: $0.00→ Common Stock (10,000 underlying)
Footnotes (5)
- [F1]The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- [F2]Represents the weighted average sale price. The lowest price at which shares were sold was $0.6831 and the highest price at which shares were sold was $0.6980. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- [F3]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
- [F4]The RSUs vested as to 1/2 of the total number of shares underlying the award on April 30, 2022 and the remainder of the RSUs vested on March 31, 2023 pursuant to an agreement between the Reporting Person and the Issuer.
- [F5]The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.